US 12,290,507 B2
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Kavitha Nellore, Bangalore (IN); and Subramanya Hosahalli, Bangalore (IN)
Assigned to Aurigene Oncology Limited, Bangalore (IN)
Filed by Aurigene Oncology Limited, Bangalore (IN)
Filed on Oct. 14, 2021, as Appl. No. 17/501,701.
Application 17/501,701 is a continuation of application No. 16/607,609, granted, now 11,147,801, previously published as PCT/IB2018/052710, filed on Apr. 19, 2018.
Application 16/607,609 is a continuation of application No. 15/899,707, filed on Feb. 20, 2018, abandoned.
Application 15/899,707 is a continuation of application No. 15/494,820, filed on Apr. 24, 2017, granted, now 9,937,155, issued on Apr. 10, 2018.
Prior Publication US 2022/0241246 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4192 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/4192 (2013.01) [A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61P 35/02 (2018.01)] 4 Claims
 
1. A method of treating a cancer selected from chronic lymphocytic leukemia, Hodgkin's disease, and follicular lymphoma, in a subject, comprising administering to the subject a therapeutically effective amount of compound 1 represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.